Data in Huntington Disease, Tardive Dyskinesia and Tourette Syndrome to Be Presented
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new data for SD-809 (deutetrabenazine) tablets will be presented at the 20th International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Berlin, June 19-23, 2016.
Teva-sponsored data evaluating SD-809 in patients with chorea associated with Huntington disease, tardive dyskinesia and tics associated with Tourette syndrome will be highlighted in clinical, preclinical and health economics data poster presentations. In addition, Teva will host a Corporate Symposium entitled, “Emerging Technologies and Therapies in Movement Disorders,” on Thursday, June 23, 2016 from 1:30 to 2:30 p.m. CEST.
“There is a significant unmet medical need, as limited options are currently available for the treatment of neurological disorders such as Huntington disease, tardive dyskinesia and Tourette syndrome,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva. “Data planned for presentation at this year’s MDS Congress demonstrates Teva’s commitment to research and helping improve the lives of patients and caregivers in these severely underserved patient communities.”
Teva-sponsored data to be presented include:
Evaluation of Quality of Life (QoL), Patient- and Clinician-Reported Outcomes with Deutetrabenazine Treatment of Chorea in Huntington Disease in First-HD (C. Testa, D. Claassen, D. Oakes, D. Stamler, V. Sung, S. Frank)
Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated Week 8 results for the switch cohort (D. Stamler)
Maintenance of balance function in patients with HD treated with deutetrabenazine, as measured by Berg balance test (BBT) in First-HD (D. Claassen, D. Oakes, D. Stamler, V. Sung, C. Testa, S. Frank)
Evaluating Swallowing Function in Patients with Huntington Disease Enrolled in the First-HD Study (D. Claassen, S. Frank, V. Sung, S. Janicki, C. Vaughan, D. Stamler, D. Oakes, C. Testa)
A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD) (H. Fernandez, S. Factor, R. Hauser, J. Jimenez-Shahed, W. Ondo, M. LeDoux, D. Shprecher, T. Simuni, D. Stamler, K. Anderson)
A Randomized Double-blind Placebo- and Positive-Controlled Crossover Study to Evaluate the Effects of Single Doses of SD-809 (Deutetrabenazine) and Tetrabenazine on the Corrected QT Interval (D. Stamler, E. Offman, M. Bradbury, L. De Boer)
A Pilot Study of SD-809 (deutetrabenazine) in Tics Associated with Tourette Syndrome (J. Jankovic, J. Jimenez-Shahed, C. Budman, B. Coffey, T. Murphy, D. Shprecher, D. Stamler)
Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the First-HD and TETRA-HD trials (D. Claassen, B. Carroll, L. De Boer, E. Wu, R. Ayyagari, S. Gandhi, D. Stamler)
Temporal course of the UHDRS chorea score in Huntington disease (T. Felong, P. Auinger, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulous, C. Venuto, R. Dorsey)
Temporal course of the Total Motor Score in Huntington disease (P. Auinger, T. Felong, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulous, C. Venuto, R. Dorsey)
Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease (D. Claassen, P. Donga, S. Rajagopalan, L. De Boer, B. Carroll, S. Gandhi)